Discussion
This case shows the regression of scleroderma following chemotherapy with the MOPP regimen and its recurrence at a time when subclinical lymphoma recurrence was possible as indicated by the presence of the monoclonal paraprotein band. We postulate a pathogenic relation explaining the coexistence of these diseases and their simultaneous resolution and recurrence. We also explore putative links between the development of scleroderma in a patient with pre-existing malignant disease, and conversely between tumour development in a patient with pre-existing connective tissue disease.
Previously published papers do not indicate a significant overall excess of malignancy in systemic sclerosis.' There is, however, an increased incidence of neoplasia in many diseases in which tissue is subjected to persistent proliferation and repair. In patients with oesophageal carcinoma in systemic sclerosis malignant change develops in tissue affected by longstanding oesophageal disease.2
There cell mediated immune process initiated by the lymphoma was responsible for the development of systemic sclerosis in our patient, and that this case suggests the possibility of identifying patients with systemic sclerosis amenable to immunotherapy and monitoring of their response using serological markers of the immune process.
Pre-existing scleroderma may be complicated by malignancy as a secondary event. Postulated explanations for this sequence of events are the same as those described here for the development of lung tumours.
The third possibility is of a common pathogenesis. A common genetic susceptibility has been considered by Forbes et al ' and Lee et al, 6 though the numbers were small and the evidence anecdotal. It We must also consider that the regression of the scleroderma may have been the result of treatment with the MOPP chemotherapeutic regimen. High doses of steroids have been used in patients with systemic sclerosis with myositis, serositis, the oedematous phase of skin disease, and refractory arthritis with some degree of success, but such treatment generally requires a higher daily dose of prednisolone taken for a longer time than the prednisolone component of the MOPP regimen. Reports of the efficacy of chlorambucil in the treatment of systemic sclerosis have been conflicting.'6 Vincristine, procarbazine, and combination chemotherapy have not been assessed as potential treatments for systemic sclerosis but such toxic drugs would carry a risk and morbidity that would probably limit their use to a life threatening situation.
Conclusions
We have reported the case of a patient whose initial presentation was that of systemic sclerosis but who went on to develop a grade Ilb nodular sclerosing Hodgkin's lymphoma. Following combination chemotherapy the tumour regressed completely followed by objective and subjective regression of the scleroderma. A year later features of systemic sclerosis recurred, this time in association with myositis and a positive test for antibodies to ribonucleoprotein. Rapid disease progression ensued and the appearance of a paraprotein band was noted suggesting subclinical lymphoma recurrence. A review of published work has shown that although there is no overall increase of carcinoma in patients with systemic sclerosis, when the two occur together a close temporal relation has been noted which suggests that one disease may influence the development or behaviour of the second. We postulate that a humoral or cell mediated immune process initiated by the lymphoma was responsible for the development of systemic sclerosis in our patient and we have speculated on the mechanisms by which tumour and connective tissue disease development and regression may interrelate. chemotherapy for lymphoma. 
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